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College of Cardiology FoundationPressure overload in arterial hypertension leads to mal-
adaptive myocardial remodeling associated with cardiac
hypertrophy and later development of heart failure with
preserved or reduced ejection fraction (1). AntihypertensiveIII (Kardiologie, Angiologie und Internistische
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2013; revised manuscript received October 7,drugs reduce cardiac remodeling (2) and progression to
heart failure (3). Resistant arterial hypertension is deﬁned
as insufﬁcient ofﬁce blood pressure (BP) control despite the
use of 3 antihypertensive drugs at maximal tolerated
doses, one being a diuretic (4). Renal artery sympathetic
denervation (RDN) is a novel technique that has been
shown to reduce BP and heart rate (HR) in patients with
resistant hypertension (5–7). HR is associated with out-
comes in hypertension (8) and heart failure (9), and HRSee page 1924reduction improves left ventricular (LV) remodeling (10)
and outcomes (11) in heart failure. RDN has also been
shown to reduce LV hypertrophy (LVH) and to improve
diastolic and systolic LV function, also achieving a decrease
of LV mass in some ofﬁce BP nonresponders (<10 mm Hg
decrease 6 months after RDN) (12). These ﬁndings
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DBP = diastolic blood
pressure
DT = deceleration time
E/A = E- to A-wave ratio
EsMWS = end-systolic
meridional wall stress
FS = fractional shortening
HR = heart rate
IVRT = isovolumetric
relaxation time
LV = left ventricular
LVEDD = left ventricular end-
diastolic diameter
LVESD = left ventricular end-
systolic diameter
LVH = left ventricular
hypertrophy
LVMI = left ventricular
mass index
LVOT = left ventricular
outﬂow tract
LVPWs = left ventricular
posterior wall during systole
RDN = renal sympathetic
denervation
SBP = systolic blood
pressure
VCFc = heart rate–corrected
left ventricular
circumferential ﬁber
shortening
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1917attracted our attention to a possible BP-independent effect
of RDN. In the present study, we thus investigated cardiac
structure and function before and 6 months after RDN
using transthoracic echocardiography and analyzed results in
relation to BP and HR reduction.
Methods
Patient selection. This study was approved by the insti-
tutional medical ethics committee (No. 67/11) in accordance
with the declaration of Helsinki. Sixty-six consecutive
patients scheduled for RDN for treatment of resis-
tant arterial hypertension (deﬁned as ofﬁce systolic BP
[SBP] 140 mm Hg) were prospectively included using
a prespeciﬁed analysis protocol (Symplicity extension
NCT00664638, NCT00888433, and NCT01888315) if
they were in sinus rhythm and did not suffer from systolic
heart failure (ejection fraction <50%) or severe renal
dysfunction (estimated glomerular ﬁltration rate <45 ml/
min/1.73 m2 as measured by cystatin C). Patients suffering
from secondary causes of hypertension were excluded.
BP and HR. Following 10 min of supine rest, BP was
measured in triplicate with an automatic oscillometric
monitor and HR was obtained from a 12-lead electrocar-
diogram. Ambulatory BP monitoring (ABPM) was per-
formed to exclude pseudoresistant hypertension (mean 24-h
SBP <130 mm Hg) (13).
Echocardiography. Transthoracic echocardiography was
performed by the same operator (M.M.Y.A.S.), who was
blinded to BP data and patient status, on a Vivid E9 (General
Electric, Frankfurt, Germany) before and 6 months after
RDN. The investigation included regular 2-dimensional
echocardiography, Doppler, and tissue Doppler imaging
according to the guidelines of the American Society of
Echocardiography (14). All studies were read ofﬂine by an
investigator blinded to patient status (S.H.S.). LV size was
measured as left ventricular end-diastolic diameter (LVEDD)
using M-mode. LV mass was calculated from the end-
diastolic diameters of the interventricular septum (IVSd),
left ventricular posterior wall (LVPWd), and LV cavity using
the Devereux formula (15). Body surface area was calculated
according to the Mosteller formula (16), and LV mass was
indexed to height to the 2.7th power. Relative wall thickness
was calculated as the sum of IVSd and LVPWd divided by
LVEDD. LV diastolic function was assessed according to
standardized criteria (17), using pulsed-wave (PW) Doppler
of the mitral inﬂow and measuring deceleration time (DT) of
the E-wave, E- to A-wave ratio (E/A), and isovolumetric
relaxation time (IVRT) (time between closure of the aortic
and opening of the mitral valve). Tissue Doppler was used for
measurements of E0 septal and E0 lateral wave (peak early
diastolic septal and lateral mitral annular velocities) and
calculation of the ratio of the maximum E-wave velocity
and the mean E0-wave. Other hemodynamic parameters
were calculated as follows: stroke volume ¼ p  VTILVOT
 (diameterLVOT/2)2, for which VTI is velocity timeintegral and LVOT is LV out-
ﬂow tract. Peripheral arterial
compliance ¼ stroke volume/
(SBP  DBP), for which DBP is
diastolic blood pressure. HR-
corrected LV circumferential ﬁber
shortening (VCFc) ¼ FS/ET 
(60/HR)1/2, for which FS is frac-
tional shortening and ET is ejection
time. End-systolic meridional wall
stress (EsMWS) was calculated
according to Grossman et al.
(18) and Reicheck et al. (19) as
follows: (0.334 SBPLVESD)/
(LVPWs  [1 þ LVPWs/
LVESD]), forwhichLVESDisLV
end-systolic diameter and LVPWs
is LV posterior wall during systole.
RDN procedure. Following renal
artery angiography, RDN was
performed using the Flex catheter
system (Medtronic, Santa Rosa,
California), as previously reported
(7). In both renal arteries, radio-
frequency ablations at a maximum
power of 8 W lasting 2 min each
were performed.
Statistical analysis. Data are
presented as mean  SEM.
Data were analyzed for nor-
mal distribution using the
Kolmogorov-Smirnov test. Nor-
mally distributed parameters
were compared between baseline
and 6-month follow-up using a
paired Student t test or a Wil-
coxon matched-pairs test if not normally distributed. Linear
regression analyses were used to calculate the correlation
between the change in BP and the change in echocardio-
graphic parameters. Analysis of variance was performed
with post-hoc testing for trend when the change in the 3
groups was compared. The Fisher exact test was used for
testing associations in 2  2 contingency tables. Differ-
ences were considered signiﬁcant if p was <0.05. SPSS
version 18.0 (SPSS Inc., Chicago, Illinois) was used for
statistical calculations.Results
Baseline characteristics. Patients in the treatment group
had a mean age of 63.5  1.2 years. Thirty-six of the 66
study patients (54.5%) were male. Average body mass
index was 29.4  0.6 kg/m2. Patients were receiving 4.3
 0.1 antihypertensive drugs (Online Table 1). The RDN
procedure was performed without complications in all
patients.
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1918RDN decreased BP, HR, and LV mass and improved
diastolic LV function. Six months after RDN, SBP/DBP
decreased from 172.9  3.0/92.5  2.3 mm Hg to 151.3 
3.2/85.5  1.6 mm Hg (p < 0.001 for both), corresponding
to a decrease of 21.6 3.0/10.1 2.0 mmHg. Pulse pressure
decreased from 81.8  2.9 mm Hg to 69.0  2.7 mm Hg
(p< 0.001). Reduction of BP was conﬁrmed by 24-h ABPM
when completely available at both time points (n ¼ 50). HR
decreased from 67.7  1.3 beats/min before to 60.5  1.2
beats/min at 6 months (p < 0.001). LV mass index (LVMI)
was reduced from 61.5  2.0 g/m2.7 before to 53.4 
1.5 g/m2.7 at 6 months (p < 0.001). E/A in mitral PW
Doppler as a measure of diastolic function increased from
0.84  0.04 to 1.01  0.06 (p ¼ 0.001) (Fig. 1). DT of PW
Doppler detected that E wave of the mitral inﬂow decreased
from 252.0  8.5 at baseline to 227.6  5.7 ms at 6 months
(p ¼ 0.010). In tissue Doppler, an improvement of diastolic
mitral annular movement was noted by an increase in E0
velocity (mean septal and lateral E0) from 6.73  0.25 cm/s
before RDN to 7.47  0.26 cm/s at follow-up (p ¼ 0.003).
MaximumE-wave velocity increased from 66.9 2.6 cm/s to
72.9  2.1 cm/s (p ¼ 0.013). Because of the increase of both
E and E0, the ratio E/E0mean as an indicator of ﬁlling pressure
was unchanged (10.6  0.5 before, 10.4  0.4 at follow-up).
SBP at baseline or SBP reduction did not inﬂuence LV
mass regression or improvement of diastolic function.
Tertiles were deﬁned according to SBP at baseline (n ¼ 22
patients each). In patients with a baseline pressure of 148.6
 1.6 mm Hg, SBP was reduced to 136.3  2.9 mm Hg in
those with a pressure of 169.5  1.7 mm Hg to 153.2  3.6
mm Hg and in those with a pressure of 200.5  3.6 mm Hg
to 164.4  7.5 mm Hg (all p < 0.001; use-dependent effect,
p for trend of SBP decrease ¼ 0.002) (Fig. 2A). Patients
were also divided into tertiles according to SBP reduction
(n ¼ 22 patients each). In the ﬁrst tertile, SBP remained
unchanged from baseline (166.5  5 mm Hg) to 6 months’
follow-up (170.8  6.3 mm Hg; p ¼ 0.081), constituting
BP nonresponders (10 mm Hg reduction). In the secondFigure 1 Renal Denervation Reduces Blood Pressure and Heart Rate
In the whole population of 66 patients, (A) systolic blood pressure (SBP) and (B) heart r
index (LVMI) and (D) E- to A-wave ratio (E/A) velocity as a measure of diastolic function rtertile, SBP was reduced by 18.6  1.1 mm Hg from 161.7
 3.1 to 143.2  3.2 mm Hg (p < 0.001). In the last tertile,
SBP was reduced by 50.4  3.9 mm Hg from 190.4  5.1
to 140.0  4.4 mm Hg (p < 0.001).
LVMI decreased by the same extent in all tertiles of
baseline SBP (from 57.6  3.2 g/m2.7 to 50.8  2.3 g/m2.7
[p ¼ 0.004] in the ﬁrst, from 64.8  3.3 g/m2.7 to 56.6 
2.4 g/m2.7 [p ¼ 0.001] in the second, and from 62.2 g/m2.7
 3.7 to 52.6  3.2 g/m2.7 [p < 0.001] in the third tertile [p
for trend of LVMI decrease ¼ 0.529]) (Fig. 2B). LVMI also
regressed comparably in all tertiles of SBP reduction: from
64.0  4.1 g/m2.7 to 53.2  2.7 g/m2.7 (p < 0.001) in the
ﬁrst, from 59.6  2.9 g/m2.7 to 51.6  2.3 g/m2.7 (p <
0.001) in the second, and from 61.7  3.3 g/m2.7 to 55.3 
3.0 g/m2.7 (p ¼ 0.002) in the third tertile. Comparable
LVMI regression was observed in all tertiles of 24-h BP at
baseline and 24-h BP reduction (measured by ABPM)
(Online Fig. 1). End-diastolic diameter of the interven-
tricular septum and the LV posterior wall decreased
accordingly in all tertiles. Linear regression analysis of the
relative change in BP and the relative change in LVMI
proved that there was no signiﬁcant interaction of the
change in SBP and LVMI regression (r2 ¼ 0.024; p ¼
0.280). The number of patients with LVH (>44 g/m2.7 for
women, >48 g/m2.7 for men) decreased from 55 patients at
baseline to 39 patients at follow-up (p ¼ 0.004). Similar to
wall thickness, LVEDD decreased in all tertiles. LVESD
and FS did not change signiﬁcantly (data not shown).
Next, the relation of diastolic function with SBP was
investigated. In the baseline SBP tertiles, E/A increased by
0.19  0.09 (p ¼ 0.018), 0.09  0.05 (p ¼ 0.064), and 0.09
 0.07 (p ¼ 0.220), respectively (p for trend of E/A
increase ¼ 0.260) (Fig. 2C). DT and IVRT were reduced in
all tertiles of baseline SBP. E/A, DT, and IVRT also im-
proved in all tertiles of SBP reduction, and linear regression
analyses conﬁrmed lack of relation of improvement of mitral
inﬂow parameters with SBP reduction (r2¼ 0.001; p¼ 0.770)
for DT, (r2 ¼ 0.000; p ¼ 0.907) for E/A, and (r2 ¼ 0.014;ate (HR) were reduced following renal denervation. Also, (C) left ventricular mass
egressed and improved, respectively.
Figure 2 Improvements in LV Mass and Diastolic Function Are Unrelated to BP
(A) SBP decreased signiﬁcantly following renal denervation in all tertiles of SBP at baseline but decreased more the higher the baseline SBP was (use-dependent effect)
(B) LVMI decreased similarly in all tertiles of SBP. (C) E/A as a measure of diastolic function increased similarly in all tertiles. Abbreviations as in Figure 1.
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1919p ¼ 0.351) for IVRT. Also, E0 velocity increased comparably
in all tertiles of SBP reduction.
HR at baseline or HR reduction does not predict LV
mass regression or improvement of diastolic function.
Although HR reduction correlated with baseline HR
(Fig. 3A), it was similar in all tertiles of baseline SBP (data not
shown). In the tertiles of SBP reduction, HR also decreased
similarly from 69.1  2.4 beats/min to 61.2  2.3 beats/min
(p < 0.001), from 64.6  2.2 beats/min to 58.1  2.3
beats/min (p¼ 0.009), and from 69.7 2.3 beats/min to 62.3
 1.7 beats/min (p ¼ 0.001) (i.e., by 9.1  3.2, 10.8  3.7,Figure 3 Improvements in LV Mass and Diastolic Function Are Unrel
(A) HR decreased signiﬁcantly following renal denervation in all tertiles of HR at baseline
(B) LVMI decreased similarly in all tertiles of HR. (C) E/A as a measure of diastolic funcand 10.9  3.1 beats/min, respectively). Linear regression
analysis corroborated lack of association ofHR reduction with
BP reduction (r2 ¼ 0.017; p ¼ 0.314). We next analyzed the
relation of HR reduction and change in LVmass. Decrease in
LVMI was present to a similar extent in all tertiles of baseline
HR and HR reduction (Fig. 3B). Increase of E/A (Fig. 3C)
and decrease of IVRT also occurred to a similar extent in all
tertiles of baseline HR and HR reduction.
SBP or HR reduction occurs independently of LVMI
reduction or change in diastolic LV function. LVMI
regression was present in all tertiles of LVMI at baselineated to HR
but decreased more the higher the baseline HR was (use-dependent effect).
tion increased similarly in all tertiles. Abbreviations as in Figure 1.
Figure 4 BP and HR Reduction Are Decreased Independently of LV Mass and Diastolic Function
In tertiles of LVMI reduction, (A) SBP and (B) HR decreased to a similar extent. In tertiles of E/A change as a parameter of diastolic function, (C) SBP and (D) HR decreased
to a similar extent. Abbreviations as in Figure 1.
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1920but showed a use-dependent effect with stronger regres-
sion the higher the baseline LVMI was (p for trend
< 0.001; data not shown). When the whole patient group
was divided into tertiles according to LVMI regression,
SBP decrease was similar across all tertiles of LVMI
regression (decrease of 30.0  5.4, 18.6  6.0, and 18.8 
5.3 mm Hg, respectively; all p < 0.01) (Fig. 4A). We also
observed HR reduction to be similar in all tertiles of LVMI
reduction (Fig. 4B). Lack of correlation of HR and LVMI
reduction was underlined in linear regression analysis
(r ¼ 0.008; p ¼ 0.478). SBP and HR reduction occurred
similarly in all tertiles of E/A increase (Figs. 4C and 4D).
A calculation of 4 groups according to the presence of a
decrease in BP and HR showed that LV mass regression
was present in all groups independent of either BP or HR
reduction (Fig. 5).
Functional cardiovascular parameters improve depending
on BP reduction. Vascular compliance increased from 1.05
 0.05 before RDN to 1.39  0.06 ml/mm Hg at 6 months
(p < 0.001). Improvement in compliance was not evident in
the ﬁrst tertile of BP reduction (1.18  0.10 ml/mm Hgbefore, 1.15  0.09 ml/mm Hg 6 months after RDN;
p ¼ 0.890), more pronounced in the second tertile (increase
from 1.17  0.08 ml/mm Hg to 1.55  0.09 ml/mm Hg;
p ¼ 0.005), and most pronounced in the tertile with
strongest BP decrease (compliance increase from 0.93 
0.06 ml/mm Hg to 1.40  0.09 ml/mm Hg; p < 0.001).
In linear regression analysis, increase in compliance was
dependent on BP decrease (r2 ¼ 0.288; p < 0.001). VCFc
was not affected by RDN (data not shown). EsMWS
decreased from 66.9  2.9 to 59.4  2.2  103 dynes/cm2
(p ¼ 0.042). Again, because of the dependency of the
calculation of the parameter on BP, its decrease was present
only in the tertile with greatest BP reduction (regression
coefﬁcient r2 ¼ 0.130; p ¼ 0.013). Interestingly, compliance
and EsMWS were not associated with HR reduction. For
calculation of contractile function independently of after-
load, VCFc was correlated with EsMWS (20,21). The
y-axis intercept, representing intrinsic contractility at a
hypothesized afterload of zero, increased mildly but signif-
icantly following RDN (from 0.746  0.062 before to 0.820
 0067 after RDN; p < 0.001) (Online Fig. 2).
Figure 5
LV Mass Decreased Evenly in Patients With
or Without BP or HR Reduction
After investigation of the 4 groups (n ¼ 16 each) according to the decrease (or not)
in BP and the decrease (or not) in HR, LV mass was reduced to the same extent in
all groups. Abbreviations as in Figure 1.
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1921Discussion
In this prospective echocardiographic study, we observed a
decrease in BP, a decline in HR, a regression of LV mass, an
improvement of LV diastolic function, and an increase in
vascular compliance following RDN. Interestingly, structural
and functional cardiac changes were not exclusively related to
BP or HR changes, suggesting a direct role of reducing the
sympathetic nervous system activity on changes of the cardiac
phenotype.
Patients in the present investigation had slightly lower
baseline BP (173/95 mm Hg) than that in previous studies
(5,12). Furthermore, we also included patients with less severe
resistant hypertension with an ofﬁce SBP 140 mm Hg
(compared with 160 mm Hg in the Symplicity trials).
Baseline BP has been identiﬁed as the strongest predictor of
BP response after RDN (22), which might, in part, account
for the relatively high rate of nonresponders (33%) found
(<10 mm Hg SBP reduction 6 months after treatment). HR
reduction as another measure of sympathetic activation
unrelated to BP reduction, however, did occur with compa-
rable efﬁcacy in all patients undergoing RDN, suggesting that
the deﬁnition of “nonresponse” may need to be extended
beyond the BP deﬁnition. RDN also appeared to lead to LVH
regression and improvement of diastolic function in patientswith moderate resistant hypertension at baseline (baseline
SBP 140 and <160 mm Hg).
Although pharmacological BP reduction can be achieved
effectively with various types of antihypertensive drugs, their
effects on LVH seem to differ, fueling discussions on anti-
hypertrophic effects independent of BP reduction (23).
Although some studies have reported comparable anti-
hypertrophic effects of different antihypertensive regimens
(24), others have shown that nonhypotensive doses of
antihypertensive drugs already inﬂuence sympathetic (beta-
adrenergic) myocardial signaling (25). The LIFE (Losartan
Intervention for Endpoint Reduction in Hypertension) study
showed greater LVH regression with angiotensin receptor
blockade than beta-blockade despite similar SBP re-
duction (26). Recently, inhibition of the renin-angiotensin-
aldosterone system and the sympathetic nervous systems
showed greater LVH regression than that produced by com-
parable BP reduction with other drugs (27). LVMI is known
to predict cardiac events (28), and reversal of LVH is associ-
ated with improved survival independent of other risk factors
(29). The present study showed for the ﬁrst time that
an interventional strategy designed for BP reduction in
treatment-resistant hypertension can reverse cardiac remod-
eling and ameliorate cardiac function in a way unrelated to BP
or HR reduction. Antihypertensive drug therapy was not to
be changed during the study period. However, medication
dosage was reduced during follow-up in 15 patients (23%),
and antihypertensive dosagewas increased in 8 patients (12%).
In a sensitivity analysis, when these 23 patients were excluded,
BP and HR changes were similar in the complete patient
group. Particularly, BP- andHR-independent changes in LV
hypertrophy remained unaffected after exclusion of these
patients, making antihypertensive drug therapy unlikely to
be the cause for the observed regression in LV mass.
In the present study, LVMI reduction was documented in
the same order of magnitude as previously reported within
6 months after RDN (12). However, patients in the current
analysis had more severe LVH, as demonstrated by a higher
LVMI at baseline (61.5 vs. 53.9 g/m2.7) than in the study by
Brandt et al. (12) and reached the same LV mass only at
follow-up (53.4 g/m2.7). Although a mild reduction in LV
mass could be observed without BP response, LV mass
regression was most pronounced in patients with the stron-
gest BP decrease. In the present investigation, LV mass
regression was as strong among BP nonresponders (ﬁrst
tertile) as compared with the other tertiles. Thus, when BP
was investigated according to tertiles of LV mass regression,
BP decreased to the same extent in all tertiles. A lack of
correlation between BP and LV mass provided statistical
evidence that modulation of the sympathetic nervous system
by RDN can reduce LVmass independently of BP. Although
no correlation was observed between baseline SBP and
LVMI, one cannot exclude that the missing correlation
between the 2 deltas are inﬂuenced by their baseline interplay
and regression to the mean, making mechanistic con-
clusions difﬁcult. Nonetheless, in other investigations, a
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1922BP-independent effect of sympathectomy on LVH has been
described in an animal model of abdominal aortic banding,
when BP was unaffected by sympathectomy but LVH
decreased signiﬁcantly (30). Pilot clinical data point toward a
reduction of total body (measured by muscle sympathetic
nerve activity [31]) and renal sympathetic activity (measured
by norepinephrine spillover [32]), which might have direct
effects on myocardial structure. Additionally, experimental
(33) and clinical data (34) using carvedilol, a combined alpha
and beta receptor blocker, point toward an alpha receptor–
mediated effect of antisympathetic treatment on LVH, which
might also underlie the observed effects of RDN.
Reduction of HR as an indicator of cardiac autonomic
activity was independent of BP reduction, conﬁrming earlier
observations (6). This is particularly relevant because HR has
been identiﬁed to be an independent predictor of mortality
in patients with arterial hypertension and heart failure
(8,35). Importantly, the present data showed that LV mass
regression and HR reduction can occur independently of
each other. We therefore conclude that both HR reduction
and LV mass regression, both of which reduce the number
of cardiovascular events (10,29), can also occur indepen-
dently of BP changes.
One could expect functional cardiac parameters in our
study to change when BP changes. However, we observed
both LVH regression and improvement of diastolic function
independently of BP change. The linear regression analyses
performed provided no evidence of BP dependency.
Improvement of vascular compliance, which was dependent
on BP reduction, was independent of HR at baseline or HR
reduction, suggesting that this BP-dependent parameter is
independent of cardiac autonomic activity.
Study limitations. Magnetic resonance imaging is consid-
ered the gold standard for the detection of LV mass (36).
However, echocardiography as a widely accessible and
inexpensive tool is known to provide valid and reproducible
LVH measurements (15). Our data on LVH regression are
conﬁrmed by unpublished but presented magnetic resonance
imaging data (37). Nevertheless, the present data are still
preliminary because they are derived from a small single-
center patient population. One cannot exclude that the
differences in ofﬁce BP and LVMI reductions found herein
were partially inﬂuenced by other factors, including a
possible regression to the mean of ofﬁce BP readings over
repeated visits.
Accurate assessment of LV ﬁlling pressure in a noninvasive
approach has limitations. The combination of tissue Doppler
and the mitral annulus and mitral inﬂow velocity curves has
been proven to yield the most valid results when compared
with invasive measurements of LV end-diastolic pressures in
left heart catheterization (38). The fact that despite
improvement in diastolic function (reduction in left atrial
volume, DT, IVRT, increase in E/A), E/E0 remained un-
changed in our study is due to a strong rise in E wave. The
latter can be explained by the HR decline induced by RDN
because HR reduction shifts ventricular ﬁlling toward theearly phase (E wave) (39). A relevant direct effect of the
decrease in BP on E/A is unlikely due to the lack of
correlation.Conclusions
RDN reduced LV mass and improved diastolic function
independently of BP and HR reduction. The current data
suggest a direct effect of the sympathetic nervous system on
myocardial morphology and function. The present ﬁndings
call for a prospective study investigating in detail the func-
tional cardiovascular beneﬁts of RDN beyond BP reduction.
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